Thymosin peptides
Explore the researchResearch Guides
Research GuidesThymosin alpha-1, beta-4 and TB-500: identify the molecule firstA practical identity map that keeps immune, tissue-repair and fragment research from being pooled together.Read guide →Research GuidesThymosin alpha-1 in cancer research: adjunct signals are not cure claimsRead the metastatic-melanoma combination trial by comparator, endpoint and statistical result.Read guide →Research GuidesAthletes: beta-4 and TB-500 are named in the 2026 prohibited listSeparate sport eligibility from approval, prescribing and claims about injury recovery.Read guide →Research GuidesThymosin beta-4 trials: keep eye drops, wound treatment and fragments separateA route-specific look at two early beta-4 studies, including negative primary endpoints in the dry-eye trial.Read guide →Research GuidesThymosin alpha-1 COVID studies: why conflicting results need design contextCompare a small hospitalized randomized trial with a multicenter cohort without turning either into an outpatient or long-COVID claim.Read guide →Research GuidesThymosin alpha-1 in hepatitis B: what did the randomized comparison test?Why two active dose groups cannot answer the same question as a placebo or current-treatment comparison.Read guide →Research GuidesHepatitis C research: thymosin alpha-1 alone and in combination are different interventionsRead a negative pilot study alongside an interferon-combination trial without borrowing benefits across regimens.Read guide →Research GuidesIntravenous beta-4 phase I studies: exposure data are not repair outcomesUnderstand what healthy-volunteer safety and pharmacokinetic studies can establish, and why they do not validate TB-500.Read guide →Research GuidesThymosin status: approval, compounding review and product identity are separate checksRead dated FDA records without mistaking a withdrawn nomination, committee discussion or foreign product name for an authorization.Read guide →Research GuidesReset-alpha and TESTS: biomarkers and survival answer different questionsCompare a short sepsis trial report with the larger TESTS publication without treating every positive measure as equivalent evidence.Read guide →Research GuidesTESTS: the large thymosin alpha-1 sepsis trial was negative overallRead the randomized trial with its May 2025 correction, including corrected mortality hazard ratios and limits.Read guide →Research GuidesThymosin alpha-1 and vaccine antibody research: what was measured?Why an antibody-response study does not automatically establish fewer infections or a recommendation for vaccine adjunct use.Read guide →